Independent Chairman of SolarEdge Technologies Avery More Buys 52% More Shares
SolarEdge Technologies, Inc. ( NASDAQ:SEDG ) shareholders (or potential shareholders) will be happy to see that ...
Trump's Election Caused a Sell-Off in Clean Energy Stocks. But Is It an Opportunity for These 2 Industry Leaders?
Trump's election has caused renewable and electric vehicle (EV) stocks to crash. But these industry leaders could be bargains.
Fintel on MSN7h
Morgan Stanley Downgrades SolarEdge Technologies (SEDG)
Fintel reports that on November 15, 2024, Morgan Stanley downgraded their outlook for SolarEdge Technologies (NasdaqGS:SEDG) ...
UBS: SolarEdge Technologies, Inc. (NASDAQ:SEDG) Is A Bottom-Ranked Quant Stock
We recently made a list of UBS’ Bottom Quant Stocks In AI, IT, Healthcare & Others: 29 Stocks In All Sectors. In this piece, ...
SolarEdge, Maxeon Solar slammed as Morgan Stanley cuts to Sell equivalent
Morgan Stanley downgrades SolarEdge and Maxeon Solar Technologies amid uncertainty surrounding the Inflation Reduction Act, ...
Trump's Win, Economic Challenges Lead to Tougher Outlook for Renewable Energy Stocks: Morgan Stanley
U.S. election results and inflation concerns pressure renewable energy stocks. Morgan Stanley downgrades key clean tech ...
FuelCell Energy to lay off 13% of workforce to reduce operating costs
Renewable power company FuelCell Energy said on Friday it will reduce 13% of its workforce as part of a global restructuring of its operations in the U.S., Canada and Germany.
SolarEdge price target lowered to $7 from $17 at Barclays
Barclays lowered the firm’s price target on SolarEdge (SEDG) to $7 from $17 and keeps an Underweight rating on the shares. The firm does ...
SolarEdge downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley downgraded SolarEdge (SEDG) to Underweight from Equal Weight with a price target of $9, down from $23. Published first on ...
Teladoc started at buy at Goldman Sachs on membership, revenue growth
Goldman Sachs initiates buy rating on Teladoc Health with $14 price target, while assigning neutral ratings on Doximity and HealthEquity. Read more here.